Provided by:
Overview
The Rhode Island Lung Cancer Screening Roundtable is a pre-recorded, interprofessional, virtual educational activity designed to improve knowledge and clinical practice related to lung cancer screening. This 90-minute session brings together primary care providers, specialists, public health professionals, and other healthcare stakeholders to explore barriers to screening, effective documentation practices, and strategies to improve access and follow-up care.
Through a moderated panel discussion featuring clinical experts and community health advocates, participants will learn to apply evidence-based workflows, utilize 2022 Lung-RADS coding for CT reporting, and successfully implement smoking history documentation as part of the lung cancer screening process. This activity also addresses interdisciplinary collaboration and innovative solutions to provider shortages, such as leveraging electronic health records and care navigation.
Target Audience
This activity is designed for primary care professionals, physicians, physician associates, nurses, community health education specialists, social workers, licensed mental health counselors, respiratory therapists, tobacco treatment specialists, and other allied members of the healthcare team caring for patients at risk for lung cancer due to current or former heavy smoking histories.
Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Identify the barriers to lung cancer screening in Rhode Island.
- Contrast evidence-based methods that facilitate lung cancer screening completion for eligible patients.
- Describe methods to improve referral systems to pulmonology.
- Classify the use of lung rads 2022 codes for lung cancer screening CT reporting and recommendations.
- Summarize the impact that smoking cessation can have on cancer incidence and mortality.
- Understand the importance of documenting smoking history properly and encouraging smoking cessation regularly.
Technology
A mobile device or computer with an internet connection is required.
Panel Members
Terrance Healey, MD – Director of Thoracic Radiology, Rhode Island Hospital; Rhode Island Medical Imaging
Hina Khan, MD – Thoracic Oncologist, Brown University Health
Paul Larson, MD, MBA – Medical Director, Brown University Health Primary Care
Andrew Foderaro, MD – Pulmonologist, Brown University Health
Robert Smith, PhD – Senior Vice President, Early Cancer Detection Science, American Cancer Society; Principal Investigator, National Lung Cancer Screening Roundtable
Cheryl Ferreira, BSN-RN, BA, BS, US Department of Veteran’s Affairs
Agenda
- Welcome (Terrance Healey, MD)
- Lung Cancer Screening: The Importance of Smoking Cessation and Non-Smoking Risk Factors (Robert Smith, PhD)
- Roundtable Discussion & Call to Action Summary (Moderator: Terrance Healey, MD)
- Hina Khan, MD/BVCHC: FQHC model program – Survivor story
- Paul Larson, MD, MBA: Using EHR to document need for screening, importance of documenting accurate smoking history, importance of HEDIS measure for LCS
- Terrance Healey, MD: Training RIMI staff, making sure diagnostic results are accompanied by next step providers
- Cheryl Ferreira, BSN-RN, BA, BS: Lung nodule clinic and triage in hospital setting
- Andrew Foderaro, MD: Ways to circumnavigate pulmonology shortage
- Reaction & Questions from Robert Smith, PhD
- Q&A
About this Activity
Medical Learning Institute Inc, University of Rhode Island College of Pharmacy, and the Partnership to Reduce Cancer in Rhode Island are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
Support
This program is supported by the Centers for Disease Control and Prevention of the US Department of Health and Human Services (HHS) as part of a cooperative agreement award (#NU58DP007118-02). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the US Government.
Planning Committee
Megan Daniel – Executive Director, Partnership to Reduce Cancer in Rhode Island
Sarah Gingrich – Coalition Coordinator/PSE Specialist, Partnership to Reduce Cancer in Rhode Island
C. Kelly Smith – Comprehensive Cancer Control Program Manager, Rhode Island Department of Health
Elizabeth Valett – Associate Director, State Partnerships, American Cancer Society
Mary-Jane Kanaczet – The University of Rhode Island- Office of Continuing Professional Development
Jean Van Couyghen-Potter – The University of Rhode Island – Office of Continuing Professional Development
Accreditation
Release Date: October 15, 2026
Expiration Date: October 15, 2028
Evaluation
All participants will have the opportunity to review the educational sessions and speakers and to identify future educational needs.
Contact Information
If you have questions regarding this activity or certificate of completion, please contact pharmce@etal.uri.edu
Registration and Requirements for CE Credit
There is no fee to participate in or receive credit for this CE activity. However, registration is required to complete the program evaluation and earn CE credit. No partial credit is available for this program.
In order to receive credit, Nurses, Physicians Associates, Physicians, Licensed Mental Health Counselors and Social Workers must participate in the CE activity by watching the entire video and completing the activity evaluation. Evaluations must be completed at www.uripharmacycpd.org. After completion of the program evaluation, CE certificates will be available from the Account History page in the learning management system and will also be emailed from confirm@uripharmacycpd.org.
If you have questions regarding the physician credit, please contact MLI at accreditation@mlieducation.org. For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
Register
- Login or create an account in URI’s learning management and CE reporting system using your email address and professional license number. Complete all required account set up fields.
- Select “Available On-Line Activities” or “Home Study Programs” to find the educational activity.
- Select Take Post-Test and use the CE code at the close of the video for your discipline.
- A certificate will be emailed once the post-test evaluation is completed.
- Registration fee for this program is There are no fees for participating in or receiving credit for this CE activity.
Statement of Disclosure
Faculty Disclosures
University of Rhode Island College of Pharmacy, the Partnership to Reduce Cancer in Rhode Island and Medical Learning Institute Inc are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Terrance Healey, MD – Rhode Island Medical Imaging – has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Hina Khan, MD – Brown Health – has a financial interest/relationship or affiliation in the form of: The following relationships have ended within the last 24 months:
Advisory Board: Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Regeneron
Paul Larson, MD, MBA – Brown Health Primary Care – has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Andrew Foderaro, MD – Brown Health – has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Robert Smith, PhD – American Cancer Society – has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Cheryl Ferreira, BSN-RN, BA, BS – has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, University of Rhode Island College of Pharmacy, and the Partnership to Reduce Cancer in Rhode Island do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.